Protagonist Therapeutics (PTGX) Research & Development (2017 - 2025)
Historic Research & Development for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $40.0 million.
- Protagonist Therapeutics' Research & Development rose 1121.21% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.8 million, marking a year-over-year increase of 1189.27%. This contributed to the annual value of $138.1 million for FY2024, which is 1495.24% up from last year.
- Per Protagonist Therapeutics' latest filing, its Research & Development stood at $40.0 million for Q3 2025, which was up 1121.21% from $37.0 million recorded in Q2 2025.
- Protagonist Therapeutics' Research & Development's 5-year high stood at $40.0 million during Q3 2025, with a 5-year trough of $24.2 million in Q1 2021.
- Its 5-year average for Research & Development is $32.8 million, with a median of $33.7 million in 2024.
- In the last 5 years, Protagonist Therapeutics' Research & Development soared by 13104.72% in 2021 and then crashed by 3126.42% in 2022.
- Quarter analysis of 5 years shows Protagonist Therapeutics' Research & Development stood at $38.4 million in 2021, then dropped by 22.12% to $29.9 million in 2022, then decreased by 3.3% to $28.9 million in 2023, then grew by 20.78% to $34.9 million in 2024, then grew by 14.61% to $40.0 million in 2025.
- Its Research & Development was $40.0 million in Q3 2025, compared to $37.0 million in Q2 2025 and $35.9 million in Q1 2025.